問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Obstetrics & Gynecology

更新時間：2024-06-03

呂建興Lu, Chien-Hsing
  • Principal Investigator
  • Clinical Trial Experience (year)

  • chlu@vghtc.gov.tw

Recruiting Trial

33Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

呂建興

List

50Cases

2020-05-01 - 2025-12-31

Phase II

Completed
A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

  • Condition/Disease

    Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

  • Test Drug

    Tiragolumab/TECENTRIQ (Atezolizumab)

Participate Sites
5Sites

Recruiting5Sites

2024-08-15 - 2026-12-31

Phase I/II

Active
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2024-04-01 - 2030-06-30

Phase III

Active
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

  • Condition/Disease

    Endometrial Cancer

  • Test Drug

    凍晶注射劑 注射液

Participate Sites
7Sites

Recruiting7Sites

2020-08-01 - 2028-06-30

Phase II

Active
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02)

  • Condition/Disease

    Trastuzumab deruxtecan will show meaningful clinical activity and a favorable risk benefit profile in selected HER2-expressing solid tumors.

  • Test Drug

    Trastuzumab deruxtecan (ENHERTUR)

Participate Sites
6Sites

Recruiting6Sites

2023-07-01 - 2030-02-28

Phase III

Active
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

  • Condition/Disease

    Locally Advanced Cervical Cancer

  • Test Drug

    Volrustomig

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2023-08-01 - 2028-03-15

Phase I

Active
FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors.

  • Condition/Disease

    Ovarian Cancer、 Lung Adenocarcinoma

  • Test Drug

    AZD5335 AZD5305

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2019-01-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2025-11-19 - 2030-06-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2025-12-27 - 2032-05-15

Phase III

Not yet recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)

  • Condition/Disease

    Endometrial Cancer 、Malignant Solid Tumour

  • Test Drug

    Frozen crystal powder for injection Solution Infusion solution Infusion solution

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2025-11-01 - 2030-05-18

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB